- -------------------------
OMB APPROVAL
- -------------------------
- -------------------------
OMB Number: 3235-0145
Expires: December 31,1997
Estimated average burden
hours per form 14.90
- -------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934*
Chrysalis International Corporation
---------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 par value per share
---------------------------------------------------------------------------
(Title of Class of Securities)
171188 10 5
-----------------------------------
(CUSIP Number)
Ray A. Mantle, Esq.
Piper & Marbury L.L.P.
1251 Avenue of the Americas
New York, New York 10020-1104
(212) 835-6180
---------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
December 18, 1996
--------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the
following box |_|.
Check the following box if a fee is being paid with the statement |_|. (A
fee is not required only if the reporting person: (1) has a previous
statement on file reporting beneficial ownership of more than five percent
of the class of securities described in Item 1; and (2) has filed no
amendment subsequent thereto reporting beneficial ownership of five
percent or less of such class.) (See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-1(a) for other parties to whom
copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
Page 1 of 9 Pages
<PAGE>
CUSIP No. 171188 10 5 Schedule 13D
- ---------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Mr. Alec Hackel
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X|
(b) |_|
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
3 SEC USE ONLY
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
4 SOURCE OF FUNDS
PF
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) |_|
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland
- ---------------------------------------------------------------------------
--------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 955,293.3
--------------------------------------------------------------
--------------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 2,547,448
--------------------------------------------------------------
--------------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON 955,293.3
--------------------------------------------------------------
--------------------------------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
2,547,448
--------------------------------------------------------------
- ---------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,547,448
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|_|
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
22.4%
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
- ---------------------------------------------------------------------------
Page 2 of 9 Pages
<PAGE>
CUSIP No. 171188 10 5 Schedule 13D
- ---------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Dr. Jack Barbut
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X|
(b) |_|
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
3 SEC USE ONLY
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
4 SOURCE OF FUNDS
PF
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) |_|
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland
- ---------------------------------------------------------------------------
--------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 955,293.3
--------------------------------------------------------------
--------------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 2,547,448
--------------------------------------------------------------
--------------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON 955,293.3
--------------------------------------------------------------
--------------------------------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
2,547,448
--------------------------------------------------------------
- ---------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,547,448
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|_|
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
22.4%
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
- ---------------------------------------------------------------------------
Page 3 of 9 Pages
<PAGE>
CUSIP No. 171188 10 5 Schedule 13D
- ---------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Dr. John Christian Jensen
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X|
(b) |_|
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
3 SEC USE ONLY
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
4 SOURCE OF FUNDS
PF
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) |_|
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
The United States of America
- ---------------------------------------------------------------------------
--------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 636,861.5
--------------------------------------------------------------
--------------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 2,547,448
--------------------------------------------------------------
--------------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON 636,861.5
--------------------------------------------------------------
--------------------------------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
2,547,448
--------------------------------------------------------------
- ---------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,547,448
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|_|
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
22.4%
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
- ---------------------------------------------------------------------------
Page 4 of 9 Pages
<PAGE>
Item 1. Security and Issuer
Common Stock, par value $.01 per share ("Common Stock")
CUSIP Number
171188 10 5
Chrysalis International Corporation ("Chrysalis")
575 Route 28
Raritan, New Jersey 08869
Item 2. Identity and Background
(a) Name
Mr. Alec Hackel ("Hackel")
Dr. Jack Barbut ("Barbut")
Dr. John Christian Jensen ("Jensen")
(b) Business Address
Mr. Alec Hackel
Flueliweg 3
6045 Meggen
Switzerland
Dr. Jack Barbut
c/o Piper & Marbury L.L.P.
1251 Avenue of the Americas
New York, New York 10020-1104
Dr. John Christian Jensen
Bohlstrasse 9a
6300 Zug
Switzerland
(c) The principal occupation of Mr. Hackel is a private
investor. Mr. Hackel is involved in numerous private
investment opportunities in Europe. The principal
business address of Mr. Hackel is Flueliweg 3, 6045
Meggen, Switzerland.
The principal occupation of Dr. Barbut is Vice
Chairman, President - Clinical Services and Director of
Chrysalis. He also is President of Chrysalis Institute
of Clinical Pharmacology GmbH (the "Chrysalis
Institute"). Chrysalis is a contract research
organization whose principal activities consist of
preclinical drug development services conducted through
its wholly-owned subsidiaries. The principal address
of Chrysalis is 575 Route 28, Raritan, New Jersey
08869. Chrysalis Institute is a contract research
organization serving the pharmaceutical, biotechnology
and medical device industries. The principal address
of Chrysalis Institute is Kronprinzenstr. 82-84,
D-40217, Dusseldorf, Germany.
Page 5 of 9 Pages
<PAGE>
The principal occupation of Dr. Jensen is President -
International Services of Chrysalis. Chrysalis is a
contract research organization whose principal
activities consist of preclinical drug development
services conducted through its wholly-owned
subsidiaries. The principal address of Chrysalis is
575 Route 28, Raritan, New Jersey 08869.
(d) None of Messrs. Hackel, Barbut or Jensen has been
convicted in a criminal proceeding within the last five
years.
(e) Within the last five years, none of Messrs. Hackel,
Barbut or Jensen has been party to a civil proceeding
before a judicial or administrative body of competent
jurisdiction wherein as a result of such proceeding any
of them was or is subject to a judgment, decree or
final order enjoining future violations of, or
prohibiting or mandating activities subject to, Federal
or State securities laws or finding any violation with
respect to such laws.
(f) Mr. Hackel is a citizen of Switzerland.
Dr. Barbut is a citizen of Switzerland resident in the
United States of America.
Dr. Jensen is a citizen of the United States of America
resident in Switzerland.
Item 3. Source and Amount of Funds or Other Consideration.
As of August 19, 1996, DNX Corporation ("DNX"), DNX
Acquisition Corporation ("Acquisition"), Messrs. Hackel,
Barbut, Jensen (collectively, the "BioClin Interest
Holders"), Sherby Corporation N.V. and BioClin, Inc., a
Delaware corporation ("BioClin U.S.") entered into a Merger
Agreement (the "Merger Agreement"). The Merger Agreement
provides for the acquisition by DNX of all of the
outstanding capital stock of BioClin U.S. in exchange for an
aggregate of 658,150 shares of DNX Common Stock. As of
August 19, 1996, DNX, Manfred Wissmann, acting solely in his
capacity as trustee ("Wissmann"), pursuant to a Trust
Agreement among Wissmann, Barbut and Hackel (the "Wissmann
Trust Agreement"), the BioClin Interest Holders, Dr. Gerald
Rittershaus, acting solely in his capacity as trustee
("Employee Trustee"), pursuant to a Trust Agreement (the
"Employee Trust Agreement") between Employee Trustee and Ms.
Christine Dune-Kraatz ("Kraatz"), Ms. Bettina Donhardt
("Donhardt"), BioClin Germany, Kilmer N.V. ("Kilmer") and
BioClin Europe entered into a Share Exchange Agreement (the
"Share Exchange Agreement"). The Share Exchange Agreement
provides for the acquisition by DNX of all of the
outstanding equity interests in BioClin Europe and, with
respect to its non-wholly-owned subsidiaries, all
outstanding equity interests in such subsidiaries held by
persons or entities not wholly-owned, directly or
indirectly, by BioClin Europe, in exchange for an aggregate
of 1,158,344 shares of DNX Common Stock. As of August 19,
1996, DNX, Dr. Gerald Rittershaus, acting solely in his
capacity as trustee ("Rittershaus"), pursuant to a Trust
Agreement among Rittershaus, Barbut and Hackel (the
"Rittershaus Trust Agreement"), the BioClin Interest Holders
and BioClin Institute entered into a Share Acquisition
Agreement (the "Share Acquisition Agreement"). The Share
Acquisition Agreement provides for the acquisition by DNX of
all outstanding equity interests in BioClin Institute in
exchange for an aggregate of 816,106 shares of DNX Common
Stock. On December 18, 1996, pursuant to the Merger
Page 6 of 9 Pages
<PAGE>
Agreement, Acquisition was merged with and into BioClin
U.S., with BioClin U.S. as the surviving corporation and a
wholly-owned subsidiary of DNX. DNX also issued 2,632,600
shares of DNX Common Stock to acquire all of the outstanding
capital stock of, or equity interests in, BioClin U.S.,
BioClin Europe, BioClin Germany, Kilmer and BioClin
Institute. Contemporaneous with these transactions, DNX
changed its name to "Chrysalis International Corporation."
Item 4. Purposes of Transaction.
The transaction combines DNX's international preclinical
drug development services with the international clinical
drug development expertise and experience of the BioClin
Group to permit a more rapid transition for a client's drug
through various preclinical to clinical stages of
development, thereby minimizing certain delays which
typically occur before a new drug is introduced to the
market. The transaction also offers the opportunity to
leverage DNX's client base to utilize the combined company's
full range of drug development services. In addition, the
transaction offers the opportunity to leverage investments
in information systems and software developed or under
development by the BioClin Group and to realize economies of
scale through centralization of management and
administrative functions.
Item 5. Interest in Securities of the Issuer.
Mr. Hackel
(a) Amount Beneficially Owned 2,547,448
Percent of Class 22.4%
(b) Number of shares as to which such person has:
(i) sole power to vote or direct the vote 955,293.3
(ii) shared power to vote or direct the vote 2,547,448
(iii)sole power to dispose or to direct the
disposition of 955,293.3
(iv) shared power to dispose or to direct the
disposition of 2,547,448
Dr. Barbut
(a) Amount Beneficially Owned 2,547,448
Percent of Class 22.4%
(b) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote 955,293.3
Page 7 of 9 Pages
<PAGE>
(ii) shared power to vote or to direct the vote 2,547,448
(iii)sole power to dispose or to direct the
disposition of 955,293.3
(iv) shared power to dispose or to direct the
disposition of 2,547,448
Dr. Jensen
(a) Amount Beneficially Owned 2,547,448
Percent of Class 22.4%
(b) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote 636,861.5
(ii) shared power to vote or to direct the vote 2,547,448
(iii)sole power to dispose or to direct the
disposition of 636,861.5
(iv) shared power to dispose or to direct the
disposition of 2,547,448
(c) Not applicable.
(d) No person except for Messrs. Hackel, Barbut and Jensen,
is known to have a right to receive or the power to
direct the receipt of dividends from, or the proceeds
from the sale of, the Chrysalis Common Stock owned by
Messrs. Hackel, Barbut and Jensen.
(e) Not applicable.
(f) Citizenship
Mr. Hackel is a citizen of Switzerland, Dr. Barbut is a
citizen of Switzerland resident in the United States of
America and Dr. Jensen is a citizen of the United
States of America resident in Switzerland.
Item 6. Contracts, Arrangements, Understandings or Relationships
with Respect to Securities of the Issuer.
Messrs. Hackel, Barbut and Jensen may be deemed to have
formed a group as a result of the informal understanding
among the parties with respect to the securities of
Chrysalis held by each party. Pursuant to this
understanding, the parties agree to vote as a bloc and to
take actions in a concerted manner.
Item 7. Material to be Filed as Exhibits.
None.
Page 8 of 9 Pages
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is
true, complete and correct.
Date: December 18, 1996 MR. ALEC HACKEL
By:/s/Ray A. Mantle, Esq.
Ray A. Mantle, Esq.*
Attorney-in-Fact
Date: December 18, 1996 DR. JACK BARBUT
/s/ Jack Barbut
Date: December 18, 1996 DR. JOHN CHRISTIAN JENSEN
/s/ John Christian Jensen
* See attached Power of Attorney.
Page 9 of 9 Pages
<PAGE>
POWER OF ATTORNEY
ALEC HACKEL hereby authorizes RAY A. MANTLE to sign and file
with the Securities and Exchange Commission on his behalf Form 3,
Form 4, Form 5, Form ID, Schedule 13-D and Schedule 13-G and any
amendments thereto, relating to his actual and deemed beneficial
ownership of shares of CHRYSALIS INTERNATIONAL CORPORATION. This
Power of Attorney is valid for twelve (12) months from the date
set forth below.
Alec Hackel
/s/ Alec Hackel
Date: December 1, 1996
